Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines

NCT ID: NCT02059941

Last Updated: 2017-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

780 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-09-30

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Management of intracranial hypertension (ICH) in patients with severe traumatic brain injury (sTBI) is crucial to their survival and optimal recovery. The evidence-based Guidelines for the Management of Severe Traumatic Brain Injury, 3rd Edition recommends use of intracranial pressure (ICP) monitors to assess ICH and guide intervention. Unfortunately, only a small percentage of the world has the resources and capability to routinely monitor ICP.

The objective of this proposal is to create and test guidelines for the treatment of severe TBI in the absence of ICP monitoring.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Management of intracranial hypertension (ICH) in patients with severe traumatic brain injury (TBI) is crucial to their survival and optimal recovery. The evidence-based Guidelines for the Management of Severe Traumatic Brain Injury, 3rd Edition recommends use of intracranial pressure (ICP) monitors to assess ICH and know when and how to intervene. Unfortunately in most areas of the world there is no access to ICP monitor technology. This means that most people with severe TBI are treated without use of ICP monitoring. There are no Guidelines and no literature on how to treat severe TBI without use of ICP monitors.

The objective of this project is to create guidelines for the treatment of severe TBI in the absence of ICP monitoring and test them. We propose to derive these guidelines by working with a team of clinicians that practice in austere environments in low-to-middle income countries (LMICs) and routinely make decisions based either on a treatment protocol, their clinical experience, or both. We will use a new, systematic and innovative technology and process to accomplish consensus for the guidelines among the clinicians. We will implement the Consensus-Based Guidelines (CBG) in resource-poor centers, some of which have prior exposure to less well developed ad hoc protocols for treatment of TBI, and others that do not have prior exposure. We will test the influence of the CBG on outcomes of severe TBI in a before/after design in these two sets of centers. In the first two years, patients will be treated according to the ad hoc protocol or according to individual clinician best judgment. Then the Guidelines will be developed, all sites will be trained in their use, and they will be used to guide treatment in all sites for the next 2 years. .We will evaluate the effect of using an ad hoc protocol by comparing outcomes between the two sets of centers before the Guidelines are developed. In each set of centers we will evaluate the effect of using the consensus-based guideline protocol compared to either no protocol or the ad hoc protocol by comparing the outcomes in the first and second periods. Finally, we will evaluate how much more the consensus-based protocol effects outcome than the ad hoc protocol by comparing the difference from the first to the second period between the two sets of sites

In accomplishing the study objectives, we will create and test a guideline for the treatment of severe TBI that could be used globally to improve outcomes for these patients. We will validate in LMICs a new, systematic and innovative technology and process to accomplish consensus that was derived in an HIC. Finally, we will train personnel in centers new to research in how to conduct high-quality scientific studies, and will extend the training for the personnel with whom we have been working, solidifying previous capacity-building efforts, and initiating new efforts.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Traumatic Brain Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-penetrating TBI
* Post-resuscitation Glasgow Coma Scale score (GCS) ≤ 8, and GCS Motor score ≤ 5, or Deterioration to those values within 48 hours of injury
* Age 13 years or older
* Consent to participate signed by Legally Authorized Representative (LAR)

Exclusion Criteria

* GCS of 3 with bilateral fixed and dilated pupils and/or decision to not actively treat prior to enrolment into study
* Prisoner
* No consent
* Non-survivable injury
* Other (e.g., Pre-injury life expectancy under 1 year)
* Pre-existing neurological disability that would not allow follow-up
Minimum Eligible Age

13 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Washington

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Randall M. Chesnut

Professor, Neurological Surgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Randall M Chesnut, MD

Role: PRINCIPAL_INVESTIGATOR

University of Washington

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Viedma

Cochabamba, , Bolivia

Site Status NOT_YET_RECRUITING

Hospital Japones

Santa Cruz de la Sierra, , Bolivia

Site Status ACTIVE_NOT_RECRUITING

Hospital San Juan de Dios

Santa Cruz de la Sierra, , Bolivia

Site Status NOT_YET_RECRUITING

Hospital San Juan de Dios

Tarija, , Bolivia

Site Status RECRUITING

Fundacion Clinica Campbell

Barranquilla, , Colombia

Site Status RECRUITING

Clinica Universitaria Rafael Uribe

Cali, , Colombia

Site Status RECRUITING

Hospital Erasmo Meoz #1

Cúcuta, , Colombia

Site Status RECRUITING

Hospital Erasmo Meoz #2

Cúcuta, , Colombia

Site Status RECRUITING

Hospital Jose Carrasco Arteaga

Cuenca, , Ecuador

Site Status RECRUITING

Hospital Espejo

Quito, , Ecuador

Site Status RECRUITING

Hospital Luis Razetti

Barcelona, , Venezuela

Site Status RECRUITING

Hospital Luis Razetti

Barinas, , Venezuela

Site Status RECRUITING

Hospital Dr. Patrocinio Penuela Ruiz

Cristobal, , Venezuela

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Bolivia Colombia Ecuador Venezuela

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Silvia Lujan, MD

Role: CONTACT

549-341-560-9239

Gustavo Petroni, MD

Role: CONTACT

549-341-485-5074

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Luis A Lavadenz, MD

Role: primary

591-72709559

Siliva Lujan, MD

Role: backup

549-3414855074

Victor Alanis, MD

Role: primary

591-70299888

Silvia Lujan, MD

Role: backup

549-3415609239

Roberto M Merida, MD

Role: primary

59170215050

Siliva Lujan, MD

Role: backup

549-3415609329

Ricardo Romero, MD

Role: primary

573-1845392258

Silvia Lujan, MD

Role: backup

549-3415609230

Oscar Pinillos, MD

Role: primary

301-3765951

Silvia Lujan, MD

Role: backup

549-3415609239

Zulma Urbina, MD

Role: primary

573-134414353

Silvia Lujan, MD

Role: backup

549-3415609239

Jairo Figeroa, MD

Role: primary

573-3138534218

Silvia Lujan, MD

Role: backup

549-3415609239

Soraya Puertas, MD

Role: primary

593-99246924

Silvia Lujan, MD

Role: backup

549-3415609239

Manuel E Jibaja, MD

Role: primary

593-99668588

Silvia Lujan, MD

Role: backup

549-3415609239

Jacobo Mora, MD

Role: primary

58-4142471196

Silvia Lujan, MD

Role: backup

549-3415609239

Rafael Davila

Role: primary

58-41456703

Silvia Lujan, MD

Role: backup

549-3415609239

Giannina B Martinez, MD

Role: primary

58-4147119190

Silvia Lujan, MD

Role: backup

549-3415609239

References

Explore related publications, articles, or registry entries linked to this study.

Alali AS, Temkin N, Barber J, Pridgeon J, Chaddock K, Dikmen S, Hendrickson P, Videtta W, Lujan S, Petroni G, Guadagnoli N, Urbina Z, Chesnut RM. A clinical decision rule to predict intracranial hypertension in severe traumatic brain injury. J Neurosurg. 2018 Sep 28;131(2):612-619. doi: 10.3171/2018.4.JNS173166. Print 2019 Aug 1.

Reference Type DERIVED
PMID: 30265194 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

44679

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Non-Invasive ICP Monitoring Study
NCT07113353 NOT_YET_RECRUITING